AbbVie Inc. (ABBV)
| Market Cap | 195.12B |
| Revenue (ttm) | 40.65B |
| Net Income (ttm) | 7.38B |
| Shares Out | 1.77B |
| EPS (ttm) | 4.57 |
| PE Ratio | 24.17 |
| Forward PE | 9.12 |
| Dividend | $5.20 |
| Dividend Yield | 4.71% |
| Trading Day | January 15 |
| Last Price | $110.52 |
| Previous Close | $110.52 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 111.20 |
| Day's Range | 109.48 - 111.56 |
| Day's Volume | 9,196,450 |
| 52-Week Range | 61.23 - 111.63 |
AbbVie Inc. has an established eight-year track record of producing outstanding returns and superior dividend growth. Created a solid growth platform consisting of industry-leading drugs, a ro...
NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurot...
AbbVie's portfolio of immunology drugs is getting a shot in the arm.
AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.
High dividend yields plus low valuations could be just the ticket for income-seeking investors.
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.
Investors have collectively made some misguided assumptions about the condition these companies are actually in.
These stocks are as solid as they come.
AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.
IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately...
AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.
These hot stocks combine healthy dividends with lasting brand names, making them some of the smartest picks on the market. The post 7 Hot Stocks That Will Keep You Energized With 3%-Plus Yield...
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
They trade at low earnings multiples and could be excellent buys for 2021.
The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future ear...
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
These safe stocks to buy have a low beta, attractive valuation and healthy dividends. Get in early this year to strengthen your portfolio.
All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 8.4% and a median increase of 6.6%.
NORTH CHICAGO, Ill., Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizu...
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Due to gains made over the past few years and our focus on building up our lower-yielding positions, the yield on the portfolio my wife and I are building fell to just over 2% last year. One o...
AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.
NORTH CHICAGO, Ill., Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's ex...
Jim Cramer: Dividend stock picks with potential market upside
Forget the bond market. If you want income, you need to find it in stocks, the "Mad Money" host said.
AbbVie (ABBV) closed at $106.50 in the latest trading session, marking a +1.03% move from the prior day.
NORTH CHICAGO, Ill., Jan. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 a...
These two pharmaceutical stocks can significantly boost your wealth in the long run.
2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.
ABBV's shares have rallied hard in recent weeks. But the market is still pricing in at least a partial failure of Humira replacements.
Without a doubt, 2020 will be a year few will ever forget. A global pandemic upended normal life for so many people.
2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.
Boost your retirement income with these stocks.
Here are three great stocks to buy if you want to invest like the Oracle of Omaha.
The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3...
I Replaced A Jumbo CD With This Eclectic Portfolio Of Value-Conscious Dividend-Paying Stocks
AbbVie and Bristol-Myers Squibb are major pharmaceuticals that have recently made large acquisitions that have significantly increased their total debt. However, both AbbVie and Bristol-Myers ...
AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.
AbbVie and VICI Properties have earned a spot on my 2021 dividend watchlist which consists of companies I am considering adding to my dividend income portfolio. AbbVie has a strong pipeline of...
Here are three great stocks positioned to outperform for patient investors.
These stocks should provide solid dividends you can count on.
Buying momentum in AT&T faded, as expected, as investors lost interest in its streaming subscription growth. Markets ignoring dividend-income stocks, as stock performance overshadows their str...
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
All three also offer attractive dividends.
With 2020 thankfully almost over, many investors are looking to next year. While there is some hope that a return to normal could be achieved by the summer, one thing is for sure: the stock ma...
NORTH CHICAGO, Ill., Dec. 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA® (ibrutinib) Prescr...
From a recession-proof stock to an out-of-favor oil play, these high dividend yielders could make you a lot of money.
About ABBV
AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocyti... [Read more...]
| Industry Drug Manufacturers-General | |
| CEO Richard Gonzalez | Employees 47,000 |
| Stock Exchange NYSE | Ticker Symbol ABBV |
Financial Performance
In 2019, AbbVie's revenue was $33.27 billion, an increase of 1.57% compared to the previous year's $32.75 billion. Earnings were $7.88 billion, an increase of 38.60%.
Analyst Forecasts
According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 117.10, which is an increase of 5.95% from the latest price.